Abstract:Background G-protein coupled receptors (GPCRs) are recognized as attractive targets for drug therapy. However, it remains poorly understood how GPCRs, except for a few chemokine receptors, regulate the progression of liver fibrosis. Here, we aimed to reveal the role of GPR65, a proton-sensing receptor, in liver fibrosis and to elucidate the underlying mechanism. Methods The expression level of GPR65 was evaluated in both human and mouse fibrotic livers. Furthermore, Gpr65 -deficient mice were treated with either bile duct ligation (BDL) for 21 d or carbon tetrachloride (CCl 4 ) for 8 weeks to investigate the role of GPR65 in liver fibrosis. A combination of experimental approaches, including Western blotting, quantitative real-time reverse transcription‑polymerase chain reaction (qRT-PCR), and enzyme-linked immunosorbent assay (ELISA), confocal microscopy and rescue studies, were used to explore the underlying mechanisms of GPR65’s action in liver fibrosis. Additionally, the therapeutic potential of GPR65 inhibitor in the development of liver fibrosis was investigated. Results We found that hepatic macrophages (HMs)-enriched GPR65 was upregulated in both human and mouse fibrotic livers. Moreover, knockout of Gpr65 significantly alleviated BDL- and CCl 4 -induced liver inflammation, injury and fibrosis in vivo, and mouse bone marrow transplantation (BMT) experiments further demonstrated that the protective effect of Gpr65 knockout is primarily mediated by bone marrow-derived macrophages (BMMs). Additionally, in vitro data demonstrated that Gpr65 silencing and GPR65 antagonist inhibited, while GPR65 overexpression and application of GPR65 endogenous and exogenous agonists enhanced the expression and release of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and transforming growth factor-β (TGF-β), all of which subsequently promoted the activation of hepatic stellate cells (HSCs) and the damage of hepatocytes (HCs). Mechanistically, GPR65 overexpression, the acidic pH and GPR65 exogenous agonist induced up-regulation of TNF-α and IL-6 via the Gαq-Ca 2+ -JNK/NF-κB pathways, while promoted the expression of TGF-β through the Gαq-Ca 2+ -MLK3-MKK7-JNK pathway. Notably, pharmacological GPR65 inhibition retarded the development of inflammation, HCs injury and fibrosis in vivo. Conclusions GPR65 is a major regulator that modulates the progression of liver fibrosis. Thus, targeting GPR65 could be an effective therapeutic strategy for the prevention of liver fibrosis.

GPR87 promotes renal tubulointerstitial fibrosis by accelerating glycolysis and mitochondrial injury

GPR97 Deficiency Ameliorates Renal Interstitial Fibrosis in Mouse Hypertensive Nephropathy

GRP/GRPR signaling pathway aggravates hyperuricemia-induced renal inflammation and fibrosis via ABCG2-dependent mechanisms

Inhibiting Aerobic Glycolysis Suppresses Renal Interstitial Fibroblast Activation and Renal Fibrosis.

Inhibition of PFKP in renal tubular epithelial cell restrains TGF-β induced glycolysis and renal fibrosis

The glycolytic enzyme PFKFB3 drives kidney fibrosis through promoting histone lactylation-mediated NF-κB family activation

PRDM16 Deficiency Triggered by TGF-β Signaling Aggravated Renal Fibrosis by Promoting Tubular Mitochondrial Dysfunction

Plk1 Promotes Renal Tubulointerstitial Fibrosis by Targeting Autophagy/lysosome Axis

Targeting the transmembrane cytokine co-receptor neuropilin-1 in distal tubules improves renal injury and fibrosis

Prostacyclin Mitigates Renal Fibrosis by Activating Fibroblast Prostaglandin I 2 Receptor.

Single cell G-protein coupled receptor profiling of activated kidney fibroblasts expressing transcription factor 21

Permissive Effect of GSK3β on Profibrogenic Plasticity of Renal Tubular Cells in Progressive Chronic Kidney Disease.

Targeting GPR65 Alleviates Hepatic Inflammation and Fibrosis by Suppressing the JNK and NF-κB Pathways.

Genetic and pharmacological inhibition of GRPR protects against acute kidney injury via attenuating renal inflammation and necroptosis

Activation of GPR120 in podocytes ameliorates kidney fibrosis and inflammation in diabetic nephropathy

THE GPR120 AGONIST TUG-891 AMELIORATES KIDNEY FIBROSIS AND INFLAMMATION IN DIABETIC NEPHROPATHY

GPR176 promotes fibroblast-to-myofibroblast transition in organ fibrosis progression

PGC1 α plays a pivotal role in renal fibrosis via regulation of fatty acid metabolism in renal tissue

Deletion of GPR81 Activates CREB/Smad7 Pathway and Alleviates Liver Fibrosis in Mice

Renal fibrosis as a hallmark of diabetic kidney disease: potential role of targeting transforming growth factor-beta (TGF-β) and related molecules

TP53RK Drives the Progression of Chronic Kidney Disease by Phosphorylating Birc5